

## DAFTAR PUSTAKA

- Adams, L. A., Lindor K. D. 2007. Nonalcoholic fatty liver disease. *Annals of Epidemiol.* 17(11): 863-9.
- Ageely, H.M., Erwa M.E. Ibrahim A.B., Husam O.M., Asim A.T., Talal O.H., *et al.* 2016. Use of BARD scoring system in non-alcoholic fatty liver disease patients and its correlation with ultrasonographic grading inGizan, Saudi Arabia. *Tropical Journal of Pharmaceutical Research.* 15(4) : 841-846.
- Ahmed, Z., Ahmed U., Walayat S., Ren J., Martin D., Moole H. *et al.* 2018. Liver Function Tests In Identifying Patients With Liver Disease. *Clinical and Experimental Gastroenterology.* 2018(11): 301-307.
- Aller, R., De Luis D. A., Izaola O., Gonzalez S. M., Conde R., Pache-co D., *et al.* 2012. Lys656Asn polymorphism of leptin receptor, leptin levels and insulin resistance in patients with non alcoholic fatty liver disease. *European Review for Medical and Pharmacological Science.* 16(3): 335-41.
- Amarapurkar, D. N., Hashimoto E., Lesmana L. A., Sollano J. D., Chen P. J., Goh K. L. 2007. How common is non-alcoholic fatty liver disease in the Asia–Pacific region and are there local differences?. *Journal of Gastroenterology and Hepatology.* 22(6): 788–93.
- American Diabetes Association(ADA). 2013. Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care.* 36(1): 67-74.
- Amiri, N., Atan D., Koushki M., *et al.* 2017. Type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis. *Gastroenterology and Hepatology From Bed to Bench,* 10(1): 1–7.
- Angulo, P., Hui J.M., Marchesini G. *et al.* 2007. The NAFLD Fibrosis Score: A Noninvasive System That Identifies Liver Fibrosis in Patients with NAFLD. *Hepatology.* 45(4): 846–854.
- Arisman. 2011. *Obesitas, Diabetes Mellitus & Dislipidemia.* Jakarta: EGC
- Baynest, H. W. 2015. Classification, Pathophysiology, Diagnosis and Management of Diabetes Mellitus. *Journal of Diabetes and Metabolism.* 6(5): 1-9.
- Bellentani S., Marino M. 2009. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). *Annals of Hepatology.* 8(1): S4-S8
- Benedict, M., Xuchen Z. 2017. Non-alcoholic fatty liver disease: An expanded review. *World Journal of Hepatology.* 9(16): 715-732.
- Bhatt, H. B. and Smith, R. J. 2015. Fatty liver disease in diabetes mellitus. *Hepato Biliary Surgery and Nutrition,* 4(2): pp. 101–108.
- Bolboaca, S. D. 2019. Medical Diagnostic Tests: A Review of Test Anatomy,

- Phases, and Statistical Treatment of Data. *Computational and Mathematical Methods in Medicine*. 2019(7) : 1-22.
- Boyer, T. D., Manns M. P., Sanyal A. J. 2012. *Zakim and Boyer's Hepatology: A textbook of Liver Disease 6th ed*. Philadelphia: Saunders.
- Braticevici C. F., Dina I., Petrisor A., Tribus L., Negreanu L., Carstoiu C. 2010. Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. *World Journal of Gastroenterology*. 16(38): 4784-91.
- Burgert, T.S., Sara E.T., James D., Robin G., Catherine W.Y., Xenophon P., et al. 2006. Alanine Aminotransferase Levels and Fatty Liver in Childhood Obesity: Associations with Insulin Resistance, Adiponectin, and Visceral Fat. *The Journal of Clinical Endocrinology & Metabolism*. 91(11) : 4287–4294
- Cahyono, S. B. 2011. Evaluation of increased serum aaaminotransferase level in asymptomatic patient. *Indonesian journal of gastroenterology, hepatology, and digestive endoscopy*. 12(2) : 109-115
- Carr, R.M., Amanke O., Vandana K. 2016. Non-alcoholic fatty liver disease: Pathophysiology and management. *HSS Author manuscript*. 45(4) : 639-65
- Chalasani, N., Zobair Y., Joel E. L., Anna M. D., Elizabeth M. B., Kenneth C., et al. 2012. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology*. 55(6) : 2005-2023
- Chalasani, N., Zobair Y., Joel E. L., Michael C., Kenneth C., Mary R., et al. 2018. The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases. *Hepatology*. 67(1) : 328-357
- Cho, N.H., Shaw J.E., Karuranga S., et al. 2018. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes research and clinical practice*. 138 : 271-281.
- Cichoż-Lach, H., Krzysztof C., Beata P.K., Jarosław S., Maria S., Tomasz L. 2016. The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease. *Medical Science Monitor*. 18(12) : CR735-740
- Cohen, J. A., Kaplan M. M. 1979. The SGOT/SGPT ratio--an indicator of alcoholic liver disease. *Digestive Diseases and Science*. 24(11): 835–8.
- Depkes RI. 2009. *Sistem kesehatan nasional*. Diakses pada 5 oktober 2021. <http://www.depkes.go.id>.
- Dogru, T., Hail G., Sait B. 2012. C reactive protein levels in non-alcoholic fatty liver disease. *Journal of hepatology*. 56(2): 503-510
- Domínguez, V. M., Rosario G. C., Jorge M. J. R., Luisa G. B., Ricardo M. O. 2013.

- Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease. *Revista española de enfermedades digestivas*. 105(7) : 409-420
- Eslam, M., Fei C., Jacob G. 2020. NAFLD in Lean Asians. *Clinical liver disease*. 16(6): 240-244
- Ewadh, M. J., Juda T. M., Ali Z. A., Mufeed E. M. 2014. Evaluation of Amylase Activity in Patients with Type 2 Diabetes Mellitus. American Journal of BioScience Babylon University. *College of Medicine, Biochemistry Dept. Hilla, Iraq*. 2(5), 171.
- Fang, K. C., Yuan L. C., Chien W. S., Yuan J. W., Keng H. L., Teh L. H., *et al.* 2017. Higher platelet counts are associated with metabolic syndrome independent of fatty liver diagnosis. *Journal of the Chinese Medical Association*. 80(3) : 125-132.
- Festi, D., Schiumerini R., Marzi L., Di Biase A. R., Mandolesi D., Montrone L., *et al.* 2013. Review article: The diagnosis of non-alcoholic fatty liver disease - availability and accuracy of non-invasive methods. *Alimentary Pharmacology & Therapeutics*. 37(4):392-400.
- Gianinni, E. G., Roberto T., Vincenzo S. 2005. Liver enzyme alteration: a guide for clinicians. *Canadian medical association journal*. 172(3): 367-379.
- Goblan, A. S., Mohammed A. A., Muhammad Z. K. 2014. Mechanism linking diabetes mellitus and obesity. *Diabetes, metabolic syndrome and obesity: targets and therapy*. 7(1): 587-591.
- Hall, P., Johnny C. 2012. What is the Real Function of the Liver 'Function' Tests?. *Ulster Med J*. 81(1) : 30-36
- Harrison, S. A., Oliver D., Arnold H. L., Gogia S. M., Brent A. N. T. 2008. Development and validation of a simple NALFD clinical scoring system for identifying patient without advanced disease. *Gut*. 57(10): 1441-47.
- Ilan, Y. 2012. Leaky gut and the liver: A role for bacterial translocation in nonalcoholic steatohepatitis. *World Journal of Gastroenterology*. 18(21): 2609-18.
- Irianto, Djoko P. 2017. *Pedoman Gizi lengkap Keluarga dan Olahragawan*. Yogyakarta: ANDI
- Jinna, S., Paras B. K. 2020. *Thrombocytopenia*. Treasure island (FL): StatPearls Publishing.
- Juliarta, I., Mulyantari N., Yasa I. 2018. Gambaran Hepatotoksisitas (ALT/AST) Penggunaan Obat Anti Tuberkulosis Lini Pertama Dalam Pengobatan Pasien Tuberkulosis Paru Rawat Inap di RSUP Sanglah Denpasar Tahun 2014. *E-Jurnal Medika*. 7(10):1-10.
- Jurnalis, T. D., Yorva S., Elfitrimelly. 2014. Peran Antioksidan pada Non Alcoholic Fatty Liver Disease (NAFLD). *Jurnal kesehatan andalas*. 3(1): 15-20.

- Kaser, S., Moschen A., Cayon A., Kaser A., Crespo J., Romero F. P. *et al.* 2005. Adiponectin and its receptors in non-alcoholic steatohepatitis. *Gut*. 54(1): 117-21.
- Kementrian Kesehatan RI. 2013. *Riset Kesehatan Dasar 2013*. Balitbangkes Kemenkes RI.
- Kementrian Kesehatan RI. 2014. *Situasi dan Analisis Diabetes*. INFODATIN : Pusat Data Dan Informasi Kementerian Kesehatan Republik Indonesia.
- Kementrian Kesehatan RI. 2018. *Riset Kesehatan Dasar 2018*. Balitbangkes Kemenkes RI.
- Kitajima, T., Toshimi K., Yuhei H., Shintaro Y., Kojiro T., Yasuhiro F., *et al.* 2015. Validation of the FIB-4 index for evaluation of fibrosis in patients with recurrent hepatitis C after living donor liver transplantation: A single center experience. *Hepatology research*. 46(8) : 752-757
- Lach, H. C., Krysztof C., Beata P. K., Jaroslaw S., Maria S., Tomasz L. 2012. The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease. *Medical science monitor*. 18(12) : CR735–CR740.
- Ledinghen, V., Vergniol J., Foucher J., Merrouche W., le Bail B. 2012. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. *Liver International: official journal of the international Association for the Study of the Liver*. 32(6): 911-8.
- Luo, R., Li X., Jiang R., Gao X., Lu Z., Hua W. 2012. Serum concentrations of resistin and adiponectin and their relationship to insulin resistance in subjects with impaired glucose tolerance. *The Journal of International Medical Research*. 40(2): 621-30.
- Mahale, A. R., Sonali D. P., Muthiah N., Merwyn F., Sonali U. 2018. Clinical relevance of reporting fatty liver on ultrasound in asymptomatic patients during routine health checkups. *Journal of international medical research*. 46(11): 4447-4454.
- Mallat, A., Lotersztajn S. 2008. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver. *AJP Gastrointestinal and Liver Physiology*. 294(2): G9-12.
- Martínez-Uña, M., Yaiza L., Carlos D., Manuel A. F., Marta G. N. 2020. Unraveling the Role of Leptin in Liver Function and Its Relationship with Liver Diseases. *International journal of molecular science*. 21(9368): 1-33
- Maxim, L. D., Ron N., Mark J. U. 2014. Screening test: a review with examples. *Inhalation toxicology*. 26(13): 811-828.
- Misra, A., Dhurandhar N. V. 2019. Current formula for calculating body mass index is applicable to Asian populations. *Nutrition and diabetes*. 9(3) : 1-3.



- Monzón, C. G., Martin P. E., Iacono O. L., Fernández B. M., Majano P. L., Apolinario A. *et al.* 2000. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. *Journal of Hepatol.* 33(5): 716-24.
- Papatheodorou, K., Maciej B., Eleni B., *et al.* 2018. Complications of Diabetes 2017. *Journal of diabetes research.* 2018(1) : 1-4.
- Perkeni. 2019. Pedoman Pengelolaan dan Pencegahan Diabetes Melitus tipe 2 Dewasa di Indonesia 2019. *Pengurus Besar Perkumpulan Endokrinologi Indonesia.*
- Pratt, D. S., Kaplan M. M. 2000. Evaluation of abnormal liver enzyme results in asymptomatic patients. *New England Journal of Medicine.* 342(17): 1266-71.
- Profil Kesehatan Kabupaten Banyumas. 2014. Pusat Data dan Informasi Kementerian Kesehatan.
- Puthakee, Z., Ronald G., Pamela K. 2018. Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome. *Canadian Journal of Diabetes.* 42(2018) : S10-S15.
- Putra, I. W. G. A. E., I M. S., Made P. K., Ni L. P. S., Ni W. S., I M. S. 2016. *Modul penelitian uji diagnostik dan skrining.* Fakultas kedokteran Universitas Udayana, Denpasar.
- Rokkam, V. R., Rajesh K. 2021. *Secondary thrombocytoasis.* Treasure island (FL): Statpearls publishing.
- Rust, M. F., Romen D., Vermehren J., Kriener S., Sadet D., Herrmann E., *et al.* 2012. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. *European Journal of Radiology.* 81(3): e325-31.
- Sastroasmoro, S., Sofyan I. 2011. *Dasar-dasar Metodologi Penelitian Klinis Edisi ke-4.* Jakarta : Sagung seto.
- Sari, G. A. C., Hery D. P., Edi S. 2012. Penyakit Perlemakan Hati Non-Alkoholik pada Sindroma Metabolik Dewasa: gambaran klinik dan hubungan antara jumlah komponen sindroma metabolik yang terganggu dengan derajat ultrasonografi. *Unpublished manuscript.* Fakultas kedokteran universitas diponegoro.
- Sergeant, E., Nigel P. 2015. *Epidemiology for field veterinarians: an introduction.* Boston : CAB International.
- Shrote, A. P., Sachin D. 2015. Clinical Evaluation of Correlation Between Diabetic Retinopathy with Modifiable, Non-Modifiable and Other Independent Risk Factors in Tertiary Set-up in Central Rural India. *journal of clinical & diagnostic research.* 9(10) : NC10-NC14.
- Siddiqui, M. S., Kavish R. P., Sherry B., Velimir A. L., Puneet P., Arun J. S. 2016. Performance of non-invasive models of fibrosis in predicting mild

- tomoderate fibrosis in patients with non-alcoholic fatty liver disease. *Liver international*. 36(4) : 572–579.
- Singh, A., Bhat T. K., Sharma O.P. 2011. Clinical Biochemistry of hepatotoxicity. *JClinical Toxicol*. S4 :001.
- Siswandari W., Vitasari I., Pugud S., Suharno, Chausar P. B. 2020. *Potensi angiotensin II sebagai biomarka deteksi dini non-alcoholic fatty liver disease pada diabetes melitus*. Unpublished manuscript.
- Siswosudarmo, R. 2017. *Tes diagnostik (diagnostic test)*. Fakultas kedokteran Universitas gadjah mada, Yogyakarta. 12 hal.
- Smeltzer, S. C., Bare B. G., Hinkle J. L., Cheever K. H. 2013. *Keperawatan medikal bedah Brunner & Suddarth ed. 12; alih bahasa: Devi Yulianti, Amelia Kimin; editor edisi Bahasa Indonesia: Eka Anisa Mardella*. Jakarta: EGC.
- Soelistijo, S. A., Novida, H., Rudijanto, A., et al. 2015. *Pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia 2015*. Edisi 1. PB Perkeni.
- Sriwaningsi, L. 2017. Hubungan obesitas dan hipertrigliseridemia dengan kejadian perlemakan hati pada usia 30-60 tahun. *Thesis*. Fakultas kedokteran universitas trisakti.
- Supariasa, I. D. N. 2013. *Penilaian Status Gizi. edited by Monica Ester*. Jakarta: EGC.
- Suryandari, A. R. 2013. Faktor-faktor yang berpengaruh terhadap kualitas hidup pasien non-alcoholic fatty liver disease. *Thesis*. Fakultas kedokteran universitas diponegoro.
- Targher, G., Lonardo A., Byrne C.D. 2018. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. *Nature Reviews Endocrinology*. 14(2) : 99-114.
- Treeprasertsuk, S., Panida P., Tanassanee S., Naruemon W.K., Piyawat K., Pisit T. 2016. Accuracy of noninvasive scoring systems to assess advanced liver fibrosis in Thai patients with nonalcoholic fatty liver disease. *Asian Biomedicine*. 10(1) : S49-S55.
- Udomsinprasert, W., Sittisak H., Yong H. 2018. Adiponectin as a novel biomarker for liver fibrosis. *World journal of hepatology*. 10(10): 1-11
- WHO. 2004. *Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies*. The lancet.
- WHO. 2019. *Classification of Diabetes Mellitus 2019*. Department for Management of Noncommunicable Diseases, Disability, Violence and Injury Prevention.
- Zelber-Sagi, S., Godos J., Salomone F. 2016. Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials. *Therapeutic Advances in Gastroenterology*. 9(3): 392-407

- Zhang, Y. N., Kathryn J. F., Gavin H., Jennifer Y. C., Ethan Z. S., Michelle B., et al. 2018. The role of imaging in obesity special feature: review article liver fat imaging- a clinical overview of ultrasound, CT, and MR imaging. *British institute of radiology*. 91(1089): 1-12.
- Zhang, J. Z., Jing J. C., Yao Y., Zhi G. S., Hongliang L. 2019. Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis. *Gene expression : the journal of liver research*. 19(3) 187-198

